Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Reaffirmed by Truist Financial
Truist Financial reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $150.00 target price on the stock. A number of other research firms have also recently commented on PRAX. Robert W. Baird initiated coverage on shares of […]
More Stories
Shoe Carnival (NASDAQ:SCVL) Cut to Sell at StockNews.com
StockNews.com lowered shares of Shoe Carnival (NASDAQ:SCVL – Free Report) from a hold rating to a sell rating in a...
Philip Mazzara Sells 2,513 Shares of Astera Labs, Inc. (NASDAQ:ALAB) Stock
Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) General Counsel Philip Mazzara sold 2,513 shares of the firm’s stock in...
Roman DBDR Tech Acquisition Enters Definitive Agreement with CompoSecure Holdings
Roman DBDR Tech Acquisition (OTCMKTS:DBDRU) recently disclosed its entry into a key agreement with CompoSecure Holdings, a move that signals...
QUALCOMM Incorporated (NASDAQ:QCOM) CAO Sells $202,120.00 in Stock
QUALCOMM Incorporated (NASDAQ:QCOM – Get Free Report) CAO Neil Martin sold 1,304 shares of the stock in a transaction on...
PriceSmart (NASDAQ:PSMT) Cut to “Hold” at StockNews.com
StockNews.com lowered shares of PriceSmart (NASDAQ:PSMT – Free Report) from a buy rating to a hold rating in a research...
Merchants Bancorp Enters Underwriting Agreement for Depositary Share Offering
On November 18, 2024, Merchants Bancorp (NASDAQ: MBIN) entered into an Underwriting Agreement with Morgan Stanley & Co. LLC, UBS...